XNK Therapeutics AB te anonse jodi a ke premye pasyan an te trete nan yon etid klinik Faz II lè l sèvi avèk dirijan otològ natirèl asasen (NK) kandida ki baze sou selil dwòg XNK an konbinezon ak antikò anti-CD38 Sanofi a Sarclisa (Isatuximab).
"Fè premye pasyan an trete ak selil NK nan etid klinik sa a se yon etap enpòtan nan devlopman klinik dirijan kandida dwòg nou an," te di Johan Aschan, CMO nan XNK Therapeutics. "Etid la ap byen pwogrese, e nou espere rezilta yo."
Etid Faz II ISA-HC-NK (EudraCT: 2020-000994-26) envestigatè aktyèl la, ouvè, randomize, kontwole, konpare premye dwòg kandida XNK a konbine avèk Isatuximab anti-CD38 Sanofi a ak Isatuximab pou kont li kòm yon tretman consolidation. transplantasyon selil souch otològ nan pasyan ki fèk dyagnostike myelom miltip. Etid klinik la pran plas nan Lopital Inivèsite Karolinska nan sit Huddinge li yo epi li anglobe yon total de 60 pasyan ak 30 pasyan nan chak bra tretman.
KISA POU RETIRE NAN ATIK SA A:
- “Having the first patient treated with NK cells in this clinical study is an important milestone in the clinical development of our leading drug candidate,”.
- The clinical study takes place at the Karolinska University Hospital at its Huddinge site and encompasses at total of 60 patients with 30 patients in each treatment arm.
- XNK Therapeutics AB te anonse jodi a ke premye pasyan an te trete nan yon etid klinik Faz II lè l sèvi avèk dirijan otològ natirèl asasen (NK) kandida ki baze sou selil dwòg XNK an konbinezon ak antikò anti-CD38 Sanofi a Sarclisa (Isatuximab).
